Boston Scientific Corp. (NYSE: BSX) won Food & Drug Administration approval for its Genesys HTA menorrhagia treatment.
The Natick, Mass.-based medical devices giant said the device treats excessive menstrual bleeding by ablating the endometrial lining of the uterus. It’s an upgrade of Boston Scientific’s HTA system featuring a new console, easier set-up, a graphic user interface and “several technology upgrades designed to improve operating performance,” according to a press release.
The Genesys enhancements won CE Mark approval in the European Union in January, according to the release.
Its competition includes a local entry, the NovaSure ablation treatment made by Bedford, Mass.-based Hologic Inc. (NSDQ:HOLX). Hologic touted the 1-millionth NovaSure procedure last summer.